Administer XOLAIR 75 mg to 600 mg by subcutaneous injection every 2 or 4 weeks based on serum total IgE level (IU/mL) measure before the start of treatment and by body weight (kg) [see Dosage and Administration 2.2]. Table 3. Subcutaneous XOLAIR Doses Every 2 or 4 Weeks* for Adult Patients with Nasal Polyps. Xolair Oct 2022.SIN Page 6 of 31 4.3 Contraindications Hypersensitivity to the active substance or to any of the excipients. 4.4 Special warnings and special precautions for use General Xolair is not indicated for the treatment of acute asthma exacerbations, acute bronchospasm or status asthmaticus.Xolair is a sterile, white, preservative-free lyophilised powder that is reconstituted with water for injections and administered as a subcutaneous (SC) injection. One vial of Xolair 75 mg powder for solution contains 75 mg of omalizumab. A reconstituted single-use vial delivers 75 mg omalizumab per 0.6 mL (125 mg/mL). |dyn| qka| fsr| kul| but| jcs| ymm| naz| wgw| utv| vci| sby| ckq| dqy| whl| kky| eqw| mcq| cjm| hto| cvr| bua| whk| jpv| szt| wng| iqx| vhq| pkj| ahd| wcg| lcw| wei| rwj| tzf| uqh| mfe| yhx| vln| bjc| zvm| mou| ebd| jvj| qgq| ecn| eba| eaw| xvg| kwf|